Monoclonal antibody · Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) · developed by Compugen
Renvistobart is a human monoclonal antibody that binds TIGIT, an immune inhibitory receptor expressed on tumor-infiltrating T lymphocytes and other immune cells. By blocking TIGIT's interaction with CD112 and CD155, it enhances CD226-mediated signaling in NK cells and CD8+ T cells. It is studied in endometrial, ovarian and head and neck cancers and solid tumors, in combination with nivolumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04570839 | Phase 1/2 | Endometrial Neoplasms | Completed | CGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrial NeoplasmsHead and Neck CancerOvarian CancerSolid Tumor
Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEN page.
See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CGEN catalysts and pipeline →